Vitamin B12 status in metformin treated patients: systematic review.
OBJECTIVE: Randomized controlled trials and observational studies have yielded inconsistent results on the effects of metformin on vitamin B12 reduction. We therefore performed a systematic review to analyze the effects of metformin on vitamin B12 concentration. METHODS: PubMed, Medline, Embase, and...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4069007?pdf=render |
id |
doaj-cdd568260f1a42fc8a2dfd507830e6b6 |
---|---|
record_format |
Article |
spelling |
doaj-cdd568260f1a42fc8a2dfd507830e6b62020-11-25T01:34:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e10037910.1371/journal.pone.0100379Vitamin B12 status in metformin treated patients: systematic review.Qilin LiuSheyu LiHeng QuanJianwei LiOBJECTIVE: Randomized controlled trials and observational studies have yielded inconsistent results on the effects of metformin on vitamin B12 reduction. We therefore performed a systematic review to analyze the effects of metformin on vitamin B12 concentration. METHODS: PubMed, Medline, Embase, and the Cochrane central registry of controlled trials were searched to identify randomized controlled trials and observational studies exploring the association between metformin and vitamin B12 concentration in patients with type 2 diabetes mellitus or polycystic ovary syndrome. The main outcome measure was changes in serum vitamin B12 concentration after 6-208 weeks of treatment with metformin, as compared with placebo or other anti-hyperglycemic therapy. RESULTS: Six randomized controlled trials met the inclusion criteria. Serum vitamin B12 concentrations were significantly lower in patients treated with metformin than in those who received placebo or rosiglitazone (mean difference [MD], -53.93 pmol/L; 95% confidence interval [CI], -81.44 to -26.42 pmol/L, P = 0.0001). Subgroup analysis identified four trials in which patients received a lower dose of metformin (<2000 mg/d) and two in which they received a higher dose (≥2000 mg/d), with MDs in vitamin B12 concentration after metformin treatment of -37.99 pmol/L (95% CI, -57.44 to -18.54 pmol/L, P = 0.0001) and -78.62 pmol/L (95% CI, -106.37 to -50.86 pmol/L, P<0.00001), respectively. CONCLUSIONS: The reduction of vitamin B12 may be induced by metformin in a dose dependent manner.http://europepmc.org/articles/PMC4069007?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qilin Liu Sheyu Li Heng Quan Jianwei Li |
spellingShingle |
Qilin Liu Sheyu Li Heng Quan Jianwei Li Vitamin B12 status in metformin treated patients: systematic review. PLoS ONE |
author_facet |
Qilin Liu Sheyu Li Heng Quan Jianwei Li |
author_sort |
Qilin Liu |
title |
Vitamin B12 status in metformin treated patients: systematic review. |
title_short |
Vitamin B12 status in metformin treated patients: systematic review. |
title_full |
Vitamin B12 status in metformin treated patients: systematic review. |
title_fullStr |
Vitamin B12 status in metformin treated patients: systematic review. |
title_full_unstemmed |
Vitamin B12 status in metformin treated patients: systematic review. |
title_sort |
vitamin b12 status in metformin treated patients: systematic review. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
OBJECTIVE: Randomized controlled trials and observational studies have yielded inconsistent results on the effects of metformin on vitamin B12 reduction. We therefore performed a systematic review to analyze the effects of metformin on vitamin B12 concentration. METHODS: PubMed, Medline, Embase, and the Cochrane central registry of controlled trials were searched to identify randomized controlled trials and observational studies exploring the association between metformin and vitamin B12 concentration in patients with type 2 diabetes mellitus or polycystic ovary syndrome. The main outcome measure was changes in serum vitamin B12 concentration after 6-208 weeks of treatment with metformin, as compared with placebo or other anti-hyperglycemic therapy. RESULTS: Six randomized controlled trials met the inclusion criteria. Serum vitamin B12 concentrations were significantly lower in patients treated with metformin than in those who received placebo or rosiglitazone (mean difference [MD], -53.93 pmol/L; 95% confidence interval [CI], -81.44 to -26.42 pmol/L, P = 0.0001). Subgroup analysis identified four trials in which patients received a lower dose of metformin (<2000 mg/d) and two in which they received a higher dose (≥2000 mg/d), with MDs in vitamin B12 concentration after metformin treatment of -37.99 pmol/L (95% CI, -57.44 to -18.54 pmol/L, P = 0.0001) and -78.62 pmol/L (95% CI, -106.37 to -50.86 pmol/L, P<0.00001), respectively. CONCLUSIONS: The reduction of vitamin B12 may be induced by metformin in a dose dependent manner. |
url |
http://europepmc.org/articles/PMC4069007?pdf=render |
work_keys_str_mv |
AT qilinliu vitaminb12statusinmetformintreatedpatientssystematicreview AT sheyuli vitaminb12statusinmetformintreatedpatientssystematicreview AT hengquan vitaminb12statusinmetformintreatedpatientssystematicreview AT jianweili vitaminb12statusinmetformintreatedpatientssystematicreview |
_version_ |
1725071024514400256 |